1. Home
  2. RENX vs XBIO Comparison

RENX vs XBIO Comparison

Compare RENX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.10

Market Cap

7.3M

Sector

N/A

ML Signal

N/A

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

N/A

Current Price

$3.01

Market Cap

7.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RENX
XBIO
Founded
2021
N/A
Country
United States
United States
Employees
6
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RENX
XBIO
Price
$0.10
$3.01
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
8.4M
25.8K
Earning Date
03-31-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.90
52 Week High
$0.35
$13.93

Technical Indicators

Market Signals
Indicator
RENX
XBIO
Relative Strength Index (RSI) 36.63 58.57
Support Level N/A $2.64
Resistance Level $0.17 $3.12
Average True Range (ATR) 0.02 0.26
MACD -0.00 0.04
Stochastic Oscillator 4.37 62.20

Price Performance

Historical Comparison
RENX
XBIO

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Share on Social Networks: